Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
- DOI
- 10.1186/s12943-023-01878-9
- Published
- 2023 Nov 4
- Container
- Molecular cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12943-023-01878-9,
title = {Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.},
author = {Bayle A and Belcaid L and Palmieri LJ and Teysonneau D and Cousin S and Spalato-Ceruso M and Aldea M and Vasseur D and Alame M and Blouin L and Soubeyran I and Nicotra C and Ngocamus M and Hollebecque A and Loriot Y and Besse B and Lacroix L and Rouleau E and Barlesi F and Andre F and Italiano A},
year = {2023},
journal = {Molecular cancer},
doi = {10.1186/s12943-023-01878-9},
url = {https://doi.org/10.1186/s12943-023-01878-9}
}RIS
TY - JOUR TI - Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study. AU - Bayle A AU - Belcaid L AU - Palmieri LJ AU - Teysonneau D AU - Cousin S AU - Spalato-Ceruso M AU - Aldea M AU - Vasseur D AU - Alame M AU - Blouin L AU - Soubeyran I AU - Nicotra C AU - Ngocamus M AU - Hollebecque A AU - Loriot Y AU - Besse B AU - Lacroix L AU - Rouleau E AU - Barlesi F AU - Andre F AU - Italiano A PY - 2023 JO - Molecular cancer DO - 10.1186/s12943-023-01878-9 UR - https://doi.org/10.1186/s12943-023-01878-9 ER -
APA
A, B., L, B., LJ, P., D, T., S, C., M, S., M, A., D, V., M, A., L, B., I, S., C, N., M, N., A, H., Y, L., B, B., L, L., E, R., F, B., F, A., & A, I. (2023). Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.. Molecular cancer. https://doi.org/10.1186/s12943-023-01878-9
Source records
- pubmed · retrieved 2026-09-26T12:35:53.130Z